Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)
News Sep 03, 2013
Debiopharm Group™ (Debiopharm) has announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
The aim of the study is to identify the dose limiting toxicity (DLT) and to estimate the maximal tolerated dose (MTD) of Debio 1347 (CH5183284) based on the safety and tolerability of the product during a daily oral administration to patients suffering from advanced solid malignancies that have an alteration of the FGFR 1, 2 or 3 genes (fibroblast growth factor receptor).
During an expansion part, the study will also evaluate the safety profile at the recommended dose of Debio 1347 (CH5183284) in a larger cohort of patients.
“We are delighted to initiate this first clinical phase I study with Debio 1347 (CH5183284)” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group. “Debio 1347 (CH5183284) is going to be developed with a companion diagnostic and we believe it could become a personalized treatment option for patients suffering from solid tumors which could significantly improve their outcomes”.
In December 2012, Debiopharm signed an exclusive license agreement with Chugai Pharmaceutical Co., Ltd for the development and commercialization of Debio 1347 (CH5183284) in all countries worldwide including Japan.
Eight months after executing the deal, Debio 1347 (CH5183284) is being tested in a phase I in several oncology centers of excellence in the USA and Europe.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018